Rhodiola rosea, folic acid, zinc and biotin (EndEP®) is able to improve ejaculatory control in patients affected by lifelong premature ejaculation: Results from a phase I‑II study
- Authors:
- Published online on: August 12, 2016 https://doi.org/10.3892/etm.2016.3595
- Pages: 2083-2087
-
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 44419 (Spandidos Publications: 27885 | PMC Statistics: 16534 )
Total PDF Downloads: 4656 (Spandidos Publications: 4243 | PMC Statistics: 413 )
Abstract
The therapeutic armamentarium currently available for the treatment of premature ejaculation (PE) is not highly satisfactory. However, phytotherapeutics appear to be an interesting option for PE management. The present study aimed to evaluate the tolerability and efficacy of a phytotherapeutic combination of Rhodiola rosea, folic acid, biotin and zinc (EndEP®) in the treatment of patients affected by lifelong PE. All patients affected by lifelong PE who were attending three Urological Institutions from July to December 2014 were enrolled in this prospective, multicentre, phase I‑II study. All patients were assigned to receive oral tablets of EndEP® (one tablet per day) for 90 days. Clinical and instrumental analyses were carried out at enrolment and at the end of the study. International Prostatic Symptom Score (IPSS), International Index of Erectile Function (IIEF)‑15, Premature Ejaculation Diagnostic Tool (PEDT) and Short Form (SF)‑36 questionnaires were used. The intravaginal ejaculation latency time (IELT) for each event was also evaluated using the stop‑watch technique. The main outcome measure was the difference from baseline in PEDT questionnaire and mean IELT at the end of the follow‑up period. In total, 91 patients (mean age, 32.3±5.6 years) were analysed. The baseline questionnaires mean scores were 1.1±1.6, 26.1±2.9, 15.3±3.4 and 98.2±0.5, for IPSS, IIEF‑15, PEDT and SF‑36, respectively. The mean IELT at baseline was 73.6±46.9s. At the follow‑up examination (90 days after the start of treatment), no statistically significant differences were identified in terms of IPSS (1.4±1.5) or IIEF‑15 (26.3±3.1) compared with the pre‑treatment values (P=0.19 and P=0.64, respectively). A statistically significant difference was detected between the mean IELT at enrolment and after treatment (73.6±46.9 vs. 102.3±60.0; P<0.001) and SF‑36 questionnaire (98.2±0.5 vs. 99.4±0.1; P<0.001). Fifty‑five patients reported improvement in the control of ejaculation (60.4%). Very few adverse events were reported (4.4%). In conclusion, it was found that EndEP® significantly improved ejaculatory control and the quality of sexual life in patients affected by lifelong PE, with a very low rate of adverse events.
Related Articles
- Anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a Chinese survey
- Evaluation of the SF‑36 questionnaire for assessment of the quality of life of endometriosis patients undergoing treatment: A systematic review and meta‑analysis
- Extracorporeal shock wave therapy in association with bromelain and escin for the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome
- Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey
- Prospective validation of patient fatigue questionnaire (FACIT‑F) for fatigue assessment in nab‑paclitaxel plus gemcitabine therapy